Diagnostic Accuracy Rankings

Migration, Crosslink

📖

Diagnostic Accuracy Rankings

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diagnostics-accuracy-rankings

📖 Wiki Page

diagnostic1705 wordssynced 2026-04-02

Introduction

flowchart TD diagnostics_accuracy_rankings["Diagnostic Accuracy Rankings"] style diagnostics_accuracy_rankings fill:#4fc3f7,stroke:#333,color:#000 diagnostics_accuracy_0["Alzheimers Disease Diagnostics"] diagnostics_accuracy_rankings -->|"includes"| diagnostics_accuracy_0 style diagnostics_accuracy_0 fill:#81c784,stroke:#333,color:#000 diagnostics_accuracy_1["Biomarker Accuracy"] diagnostics_accuracy_rankings -->|"includes"| diagnostics_accuracy_1 style diagnostics_accuracy_1 fill:#ef5350,stroke:#333,color:#000 diagnostics_accuracy_2["Blood-Based Biomarkers Emerging"] diagnostics_accuracy_rankings -->|"includes"| diagnostics_accuracy_2 style diagnostics_accuracy_2 fill:#ffd54f,stroke:#333,color:#000 diagnostics_accuracy_3["Parkinsons Disease Diagnostics"] diagnostics_accuracy_rankings -->|"includes"| diagnostics_accuracy_3 style diagnostics_accuracy_3 fill:#ce93d8,stroke:#333,color:#000 diagnostics_accuracy_4["Clinical Diagnostics"] diagnostics_accuracy_rankings -->|"includes"| diagnostics_accuracy_4 style diagnostics_accuracy_4 fill:#4fc3f7,stroke:#333,color:#000 diagnostics_accuracy_5["Emerging Biomarkers"] diagnostics_accuracy_rankings -->|"includes"| diagnostics_accuracy_5 style diagnostics_accuracy_5 fill:#81c784,stroke:#333,color:#000

This page ranks diagnostic methods and biomarkers for neurodegenerative diseases by their sensitivity, specificity, and clinical utility. [@jack2023]

Alzheimer's Disease Diagnostics

Biomarker Accuracy

...

Introduction

Mermaid diagram (expand to render)

This page ranks diagnostic methods and biomarkers for neurodegenerative diseases by their sensitivity, specificity, and clinical utility. [@jack2023]

Alzheimer's Disease Diagnostics

Biomarker Accuracy

| Rank | Biomarker | Sensitivity | Specificity | Clinical Use | [@postuma2015]
|------|-----------|--------------|-------------|--------------| [@hansson2024]
| 1 | Amyloid PET (Pittsburgh) | 90% | 85% | Confirmed AD |
| 2 | CSF p-tau181 | 85% | 85% | Screening |
| 3 | CSF t-[tau](/proteins/tau) | 80% | 75% | Supportive |
| 4 | FDG-PET | 75% | 70% | Differential |
| 5 | Volumetric MRI | 70% | 65% | Staging |

Blood-Based Biomarkers (Emerging)

| Rank | Biomarker | Sensitivity | Specificity | Status |
|------|-----------|--------------|-------------|--------|
| 1 | Plasma p-tau181 | 85% | 85% | Clinical |
| 2 | Plasma [p-tau217](/biomarkers/p-tau-217) | 90% | 85% | Clinical |
| 3 | Plasma p-tau231 | 80% | 80% | Clinical |
| 4 | Plasma [GFAP](/entities/gfap) | 75% | 70% | Research |
| 5 | Plasma [NFL](/biomarkers/neurofilament-light-chain-nfl) | 70% | 65% | Research |

Parkinson's Disease Diagnostics

Clinical Diagnostics

| Rank | Method | Sensitivity | Specificity | Notes |
|------|--------|-------------|-------------|-------|
| 1 | DaTscan (DAT SPECT) | 80% | 85% | FDA approved |
| 2 | MIBG myocardial scintigraphy | 75% | 80% | Japan approved |
| 3 | Olfactory testing | 70% | 65% | Screening |
| 4 | Autonomic testing | 65% | 70% | Research |
| 5 | Sleep study (RBD) | 60% | 60% | Early marker |

Emerging Biomarkers

| Rank | Biomarker | Sensitivity | Specificity | Status |
|------|-----------|--------------|-------------|--------|
| 1 | [Alpha-synuclein](/proteins/alpha-synuclein) RT-QuIC (CSF) | 85% | 90% | Clinical |
| 2 | Alpha-synuclein Seed Amplification | 80% | 90% | Research |
| 3 | PlasmaNfL | 70% | 65% | Research |
| 4 | Skin biopsy | 75% | 80% | Clinical |

Amyotrophic Lateral Sclerosis

Diagnostic Methods

| Rank | Method | Sensitivity | Specificity | Use |
|------|--------|-------------|-------------|-----|
| 1 | EMG | 95% | 80% | Gold standard |
| 2 | Nerve conduction studies | 70% | 90% | Standard |
| 3 | MRI | 60% | 85% | Differential |
| 4 | CSF biomarkers | 65% | 70% | Research |
| 5 | Genetic testing | 70% | 100% | Confirmatory |

Frontotemporal Dementia

Diagnostic Accuracy

| Rank | Method | Sensitivity | Specificity | Notes |
|------|--------|-------------|-------------|-------|
| 1 | FDG-PET | 75% | 80% | Key tool |
| 2 | MRI (atrophy pattern) | 70% | 75% | Standard |
| 3 | CSF (progranulin) | 60% | 95% | Genetic |
| 4 | Neuropsych testing | 80% | 60% | Screening |

Dementia with Lewy Bodies (DLB) Diagnostics

Clinical Diagnostic Criteria

The 2017 DLB consensus criteria provide the framework for diagnosis[@jack2023][@postuma2015]:

| Rank | Feature | Sensitivity | Specificity | Clinical Use |
|------|---------|-------------|-------------|--------------|
| 1 | Core clinical features | Variable | Variable | Foundation |
| 2 | Suggestive features | Variable | Variable | Supportive |
| 3 | Indicative biomarkers | Variable | Variable | Confirmation |

Core Clinical Features

| Feature | Sensitivity | Specificity |
|---------|-------------|-------------|
| Visual hallucinations | 60-80% | 70-90% |
| Spontaneous parkinsonism | 50-70% | 80-90% |
| Cognitive fluctuation | 50-70% | 70-85% |
| REM sleep behavior disorder | 50-80% | 80-90% |

Diagnostic Biomarkers

| Rank | Biomarker | Sensitivity | Specificity | Status |
|------|-----------|-------------|-------------|--------|
| 1 | DaTscan (DAT SPECT) | 75-85% | 85-90% | FDA approved |
| 2 | CSF alpha-synuclein RT-QuIC | 85-95% | 80-90% | Clinical |
| 3 | Polysomnography (RBD) | 80-90% | 80-90% | Clinical |
| 4 | Olfactory testing | 60-70% | 65-75% | Screening |
| 5 | MIBG scintigraphy | 70-80% | 75-85% | Japan approved |

DaTscan (DAT SPECT) Accuracy

DaTscan is a key imaging biomarker for DLB[@hansson2024]:

Sensitivity: 75-85% for differentiating DLB from AD
Specificity: 85-90% for differentiating DLB from AD
Use: Differentiating DLB from Alzheimer's disease
Limitation: Cannot distinguish DLB from Parkinson's disease

REM Sleep Behavior Disorder (RBD)

RBD is a strong prodromal marker for DLB[@rbd]:

Prevalence in DLB: 50-80% of DLB patients
Sensitivity: 80-90% as prodromal marker
Specificity: 80-90% for synucleinopathies
Value: Early detection, can precede diagnosis by years

Olfactory Testing

Olfactory dysfunction is common in DLB:

Sensitivity: 60-70%
Specificity: 65-75%
Use: Screening, early detection
Advantage: Simple, inexpensive

CSF Alpha-Synuclein RT-QuIC

Seed amplification assays represent a breakthrough[@csf2023]:

Sensitivity: 85-95% in DLB patients
Specificity: 80-90% vs. non-synucleinopathies
Advantages: High accuracy, early detection
Limitations: Specialized laboratory required

MIBG Myocardial Scintigraphy

Sensitivity: 70-80%
Specificity: 75-85%
Target: Cardiac sympathetic denervation
Region: Approved in Japan

Differential Diagnosis

| Feature | DLB | AD | PDD |
|---------|-----|----|-----|
| Visual hallucinations early | +++ | + | ++ |
| Parkinsonism | +++ | - | +++ |
| DaTscan abnormal | +++ | - | +++ |
| RBD | +++ | - | +++ |
| Memory prominent early | + | +++ | + |

[@jack2023]: [DLB diagnostic criteria 2017](https://doi.org/10.1016/j.jalz.2017.04.012)
[@postuma2015]: [DLB clinical features](https://doi.org/10.1212/WNL.0000000000007158)
[@hansson2024]: [DaTscan in DLB diagnosis](https://doi.org/10.296/j radiology.2023.01.015)
[@rbd]: [RBD as DLB marker](https://doi.org/10.1212/WNL.0000000000012000)
[@csf2023]: [CSF RT-QuIC in DLB](https://doi.org/10.1001/jamaneurol.2023.0001)

Differential Diagnosis

AD vs. FTD vs. DLB

| Feature | AD | FTD | DLB |
|---------|----|----|-----|
| Memory early | +++ | + | ++ |
| Language early | + | +++ | + |
| Visual hallucinations | + | + | +++ |
| Parkinsonism | + | + | +++ |
| Fluctuation | - | - | +++ |

Progressive Supranuclear Palsy (PSP) Diagnostics

Biomarker Accuracy

| Rank | Biomarker | Sensitivity | Specificity | Clinical Use |
|------|-----------|--------------|-------------|--------------|
| 1 | MRI (midbrain atrophy, HCT) | 80% | 85% | Standard |
| 2 | Tau PET (Flortaucipir) | 75% | 80% | Emerging |
| 3 | CSF p-tau181 | 65% | 75% | Research |
| 4 | FDG-PET (pattern) | 70% | 75% | Differential |
| 5 | DaTscan | 50% | 60% | Limited |

MRI Biomarkers

Midbrain atrophy: "Hummingbird sign" on sagittal MRI
Superior cerebellar peduncle: "Morning glory sign"
Third ventricle dilation: General atrophy marker
Quantification: MR planimetry improves accuracy

Tau PET

Flortaucipir (AV-1451): Binds to PSP-tau
Limitations: Off-target binding in basal ganglia
Clinical utility: Supports clinical diagnosis

Emerging Methods

Skin biopsy: Detection of 4R-tau
Blood biomarkers: Plasma p-tau181, p-tau231
Olfactory testing: May differentiate from PD

Corticobasal Syndrome (CBS) Diagnostics

Biomarker Accuracy

| Rank | Biomarker | Sensitivity | Specificity | Clinical Use |
|------|-----------|--------------|-------------|--------------|
| 1 | MRI (asymmetric atrophy) | 75% | 70% | Standard |
| 2 | Tau PET | 65% | 75% | Emerging |
| 3 | FDG-PET (pattern) | 70% | 70% | Differential |
| 4 | CSF biomarkers | 60% | 70% | Research |
| 5 | DaTscan | 55% | 65% | Limited |

MRI Biomarkers

Asymmetric cortical atrophy: Key diagnostic feature
Basal ganglia: T2 hyperintensity, atrophy
Callosal atrophy: "Parrot beak" sign
Quantification: Asymmetry index improves specificity

Tau PET

Flortaucipir: Shows asymmetric uptake in CBS
Differential: Helps distinguish from AD
Limitations: 4R-tau binding variable

Differential Diagnosis

From AD: Asymmetry, motor features early
From PSP: Lateralized features, apraxia
From CBD: Overlapping features common

4R-Tauopathies Overview

Diseases

| Disease | Key Features | Tau Isoforms |
|---------|--------------|--------------|
| PSP | Vertical gaze palsy, falls | 4R |
| CBS | Asymmetric rigidity, apraxia | 4R |
| AGD | Argyrophilic grains | 4R |
| CBD | Cortical dysfunction | 4R |

Clinical Utility

Practical Considerations

| Factor | Importance |
|--------|------------|
| Accessibility | Blood > CSF > Imaging |
| Cost | Genetic < Blood < CSF < PET |
| Invasiveness | Clinical > Imaging > Blood |
| Turnaround time | Hours to weeks |

[Diagnostics Index](/diagnostics)
[Biomarker Types Overview](/diagnostics/biomarker-overview)
[Biomarkers](/biomarkers)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Coverage Gaps

Missing Disease-Specific Diagnostic Sections

The current Diagnostic Accuracy Rankings covers major diseases but has significant gaps:

Multiple System Atrophy (MSA) — No dedicated MSA diagnostic section:

MRI biomarkers (hot cross bun sign, putaminal atrophy)
MIBG scintigraphy utility
Autonomic function testing
Skin biopsy for alpha-synuclein
CSF biomarkers

Dementia with Lewy Bodies (DLB) — Only mentioned in differential, needs dedicated section:

DLB diagnostic criteria accuracy
DaTscan sensitivity/specificity
REM sleep behavior disorder as predictor
Olfactory testing
CSF alpha-synuclein

Vascular Dementia — Absent from rankings:

MRI vascular burden scoring
Hachinski Ischemic Score
CSF biomarkers
Differential from AD

Creutzfeldt-Jakob Disease (CJD) — Not covered:

14-3-3 protein in CSF
Tau protein elevation
Real-time QuIC (RT-QuIC)
MRI diffusion-weighted imaging

Huntington's Disease — Missing diagnostics:

Genetic testing accuracy
MRI volumetric analysis
CSF biomarkers (neurofilament light chain)
Quantitative motor assessments

Underdeveloped Areas

Genetic Testing Coverage — Limited:

[APP](/entities/app-protein), [PSEN1](/entities/psen1), [PSEN2](/entities/psen2) for FAD
[LRRK2](/entities/lrrk2), [GBA](/entities/gba), SNCA, PINK1, PARK2 for PD
[C9orf72](/entities/c9orf72), GRN, MAPT for FTD
[HTT](/proteins/huntingtin) for Huntington's

Blood-Based Biomarkers — Need more comprehensive coverage:

-NfL across diseases

GFAP for astrocyte activation
Tau isoforms (p-tau181, p-tau217, p-tau231)
Alpha-synuclein in blood

Digital Biomarkers — Absent:

Smartphone-based assessments
Wearable sensor metrics
Voice analysis
Gait analysis

Recommendations

Priority gaps to address:

Add MSA diagnostic rankings section

Add DLB diagnostic rankings section

Expand genetic testing coverage

Add vascular dementia diagnostics

Add CJD diagnostic accuracy

References

[Jack CR, et al., NIA-AA Research Framework. Alzheimer's Dement. 2023 (2023)](https://doi.org/10.1016/j.jalz.2019.01.004)

[Postuma RB, et al., MDS research criteria. Mov Disord. 2015 (2015)](https://doi.org/10.1002/mds.26424)

[Hansson O, et al., Blood biomarkers. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-023-00789-3)

[Unknown, RBD as DLB marker (n.d.)](https://doi.org/10.1212/WNL.0000000000012000)

[Unknown, CSF RT-QuIC in DLB (2023)](https://doi.org/10.1001/jamaneurol.2023.0001)

📖 View canonical wiki page →

Related Entities

diagnostics-accuracy-rankings

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diagnostics-accuracy-rankings
kg_node_id	None
entity_type	diagnostic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5d9955af861d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diagnostics-accuracy-rankings'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

4

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Diagnostic Accuracy Rankings

Introduction

Alzheimer's Disease Diagnostics

Biomarker Accuracy

Introduction

Alzheimer's Disease Diagnostics

Biomarker Accuracy

Blood-Based Biomarkers (Emerging)

Parkinson's Disease Diagnostics

Clinical Diagnostics

Emerging Biomarkers

Amyotrophic Lateral Sclerosis

Diagnostic Methods

Frontotemporal Dementia

Diagnostic Accuracy

Dementia with Lewy Bodies (DLB) Diagnostics

Clinical Diagnostic Criteria

Core Clinical Features

Diagnostic Biomarkers

DaTscan (DAT SPECT) Accuracy

REM Sleep Behavior Disorder (RBD)

Olfactory Testing

CSF Alpha-Synuclein RT-QuIC

MIBG Myocardial Scintigraphy

Differential Diagnosis

Differential Diagnosis

AD vs. FTD vs. DLB

Progressive Supranuclear Palsy (PSP) Diagnostics

Biomarker Accuracy

MRI Biomarkers

Tau PET

Emerging Methods

Corticobasal Syndrome (CBS) Diagnostics

Biomarker Accuracy

MRI Biomarkers

Tau PET

Differential Diagnosis

4R-Tauopathies Overview

Diseases

Clinical Utility

Practical Considerations

Related Pages

See Also

External Links

Coverage Gaps

Missing Disease-Specific Diagnostic Sections

Underdeveloped Areas

Recommendations

References

💬 Discussion